Medindia LOGIN REGISTER
Medindia

New Subtype of Prostate Cancer Identified by Loss of Gene CDK12

by Adeline Dorcas on Jun 18 2018 11:49 AM

New Subtype of Prostate Cancer Identified by Loss of Gene CDK12
New subtype of prostate cancer identified by loss of gene CDK12, reports a new study. The findings of the study are published in the journal Cell.
Researchers have identified a new subtype of prostate cancer that occurs in about seven percent of patients with advanced disease.

The subtype is characterized by loss of the gene CDK12. It was found to be more common in metastatic prostate cancer compared to early-stage tumors that had not spread.

"Because prostate cancer is so common, seven percent is a significant number," said senior study author Arul Chinnaiyan from the University of Michigan in the US.

Tumors in which CDK12 was inactivated were responsive to immune checkpoint inhibitors, a type of immunotherapy treatment that has overall had limited success in prostate cancer, the study said.

"The fact that immune checkpoint inhibitors may be effective against this sub-type of prostate cancer makes it even more significant. This is an exciting prospect for patients who have CDK12 alterations and may benefit from immunotherapy," Chinnaiyan added.

The researchers said they would lead a multisite clinical trial to assess checkpoint inhibitors as a treatment for metastatic prostate cancer with CDK12 loss.

Advertisement
In this study, the researchers looked at DNA and RNA sequencing data from 360 tumor samples from patients with metastatic castration-resistant prostate cancer.

This is an aggressive, advanced form of the disease in which cancer has spread throughout the body and no longer responds to traditional hormone-based treatments.

Advertisement
The researchers found a loss of CDK12 in only about one percent of early prostate cancer samples. That jumped to 7 percent for metastatic cancer, which indicates a more aggressive form of the disease.

By following the mechanism of how CDK12 loss impacts the cell, the researchers found a process in which cells create neoantigens that are foreign to the immune system.

This boosts immune-fighting T-cells, which may explain why these patients benefit from immune checkpoint blockade.

Source-IANS


Recommended Readings
Latest Cancer News
View All
Advertisement